References
- Rajput A, et al. Levodopa efficacy and pathological basis of Parkinson syndrome. Clinical neuropharmacology. 1990; 13(6): 553–558. DOI: 10.1097/00002826-199012000-00007
- Rajput AH, et al. Clinical–pathological study of levodopa complications. Movement disorders: official journal of the Movement Disorder Society. 2002; 17(2): 289–296. DOI: 10.1002/mds.10031
- Guadagnolo D, et al. Genotype-phenotype correlations in monogenic Parkinson disease: A review on clinical and molecular findings. Frontiers in Neurology. 2021; 12:
648588 . DOI: 10.3389/fneur.2021.648588 - Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. The Lancet Neurology. 2006; 5(4): 355–363. DOI: 10.1016/S1474-4422(06)70411-2
- Wickremaratchi M, Ben-Shlomo Y, Morris HR. The effect of onset age on the clinical features of Parkinson’s disease. European journal of neurology. 2009; 16(4): 450–456. DOI: 10.1111/j.1468-1331.2008.02514.x
- Mackels L, Moïse M, Depierreux F. Multimodal imaging of a patient with RAB39B mutation. Neuroradiology. 2022; 64(3): 621–625. DOI: 10.1007/s00234-021-02882-w
- Riboldi GM, et al. A practical approach to early-onset parkinsonism. Journal of Parkinson’s disease. 2022; 12(1): 1–26. DOI: 10.3233/JPD-212815
- Wilson GR, et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology. The American Journal of Human Genetics. 2014; 95(6): 729–735. DOI: 10.1016/j.ajhg.2014.10.015
- Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Archives of neurology. 1999; 56(5): 529–535. DOI: 10.1001/archneur.56.5.529
- Kieburtz K. Therapeutic strategies to prevent motor complications in Parkinson’s disease. Journal of neurology. 2008; 255: 42–45. DOI: 10.1007/s00415-008-4007-4
- Cilia R, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014; 137(10): 2731–2742. DOI: 10.1093/brain/awu195
- Camerucci E, et al. Early-Onset Parkinsonism and Early-Onset Parkinson’s Disease: A Population-Based Study (2010–2015). J Parkinsons Dis. 2021; 11(3): p. 1197–1207. DOI: 10.3233/JPD-202464
- Turcano P, et al. Levodopa-induced dyskinesia in Parkinson disease: a population-based cohort study. Neurology. 2018; 91(24): e2238–e2243. DOI: 10.1212/WNL.0000000000006643
- Mehanna R, et al. Comparing clinical features of young onset, middle onset and late onset Parkinson’s disease. Parkinsonism & related disorders. 2014; 20(5): 530–534. DOI: 10.1016/j.parkreldis.2014.02.013
- Kostic V, et al. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology. 1991; 41(2 Part 1): 202–202. DOI: 10.1212/WNL.41.2_Part_1.202
- Leaver K, et al. Clinical profiles and outcomes of deep brain stimulation in G2019S LRRK2 Parkinson disease. Journal of Neurosurgery. 2022; 137(1): 184–191. DOI: 10.3171/2021.7.JNS21190
- Kuusimäki T, et al. Deep brain stimulation for monogenic Parkinson’s disease: a systematic review. Journal of Neurology. 2020; 267: 883–897. DOI: 10.1007/s00415-019-09181-8
- Artusi CA, et al. Association of subthalamic deep brain stimulation with motor, functional, and pharmacologic outcomes in patients with monogenic Parkinson disease: a systematic review and meta-analysis. JAMA network open. 2019; 2(2):
e187800–e187800 . DOI: 10.1001/jamanetworkopen.2018.7800 - Laxova R, et al. An X-linked recessive basal ganglia disorder with mental retardation. American journal of medical genetics. 1985; 21(4): 681–689. DOI: 10.1002/ajmg.1320210409
- Gregg RG, et al. Waisman syndrome, a human X-linked recessive basal ganglia disorder with mental retardation: localization to Xq27. 3-qter. Genomics. 1991; 9(4): 701–706. DOI: 10.1016/0888-7543(91)90363-J
- Lesage S, et al. Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease. Neurology Genetics. 2015; 1(1). DOI: 10.1212/NXG.0000000000000009
- Mata IF, et al. The RAB39B p. G192R mutation causes X-linked dominant Parkinson’s disease. Molecular neurodegeneration. 2015; 10(1): 1–8. DOI: 10.1186/s13024-015-0045-4
- Shi Ch, et al. A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification. Movement Disorders. 2016; 31(12): 1905–1909. DOI: 10.1002/mds.26828
- Ciammola A, et al. X-linked Parkinsonism with Intellectual Disability caused by novel mutations and somatic mosaicism in RAB39B gene. Parkinsonism & Related Disorders. 2017; 44: 142–146. DOI: 10.1016/j.parkreldis.2017.08.021
- Güldner M, et al. Broad clinical phenotype in Parkinsonism associated with a base pair deletion in RAB39B and additional POLG variant. Parkinsonism & Related Disorders. 2016; 31: 148–150. DOI: 10.1016/j.parkreldis.2016.07.005